TABLE 1.
Outcome and assessment points1
| Assessment point | ||||
|---|---|---|---|---|
| Variable | Measure | Set 1 | Set 2 | Set 3 |
| Primary outcomes | ||||
| Continuous glucose concentration | ||||
| PMG | FreeStyle Libre Flash glucose monitoring system | ● | ● | ● |
| AUC24 | ● | ● | ● | |
| MAGE | ● | ● | ● | |
| Secondary outcomes | ||||
| Lipid metabolism | Blood samples | |||
| Inflammation | Blood samples | |||
| Oral microbiota | Saliva | √ | √ | √ |
| Gut microbiota profiling | Fecal samples | √ | √ | √ |
| Fecal metabolites | Fecal samples | √ | √ | √ |
| Metabolomics profiling | Blood samples | |||
| Fecal samples | √ | √ | √ | |
| Urine samples | √ | √ | √ | |
| Physiological characteristics | ||||
| Weight | Kubei height scale | √ | √ | √ |
| Blood pressure | YUWELL YE660D upper arm sphygmomanometer | √ | √ | √ |
1AUC24, total area under the continuous glucose monitoring curve from 0:00 to 24:00; MAGE, mean amplitude of glycemic excursions; PMG, postprandial maximum glucose. ● = per day during intervention periods; √ = before and after intervention periods.